Equities

EKF Diagnostics Holdings PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

EKF Diagnostics Holdings PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)25.00
  • Today's Change0.40 / 1.63%
  • Shares traded40.80k
  • 1 Year change-4.03%
  • Beta0.2375
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EKF Diagnostics Holdings plc is a diagnostics and biotechnology company specializing in the manufacturing and distribution of advanced medical technologies and patient-focused solutions. The Company develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. It provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. It offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. It also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. It provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. It supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.

  • Revenue in GBP (TTM)50.22m
  • Net income in GBP6.12m
  • Incorporated2002
  • Employees297.00
  • Location
    EKF Diagnostics Holdings PLCAvon HSE, 19 Stanwell RoadPENARTH CF64 2EZUnited KingdomGBR
  • Phone+44 292 071 0570
  • Fax+44 292 070 5715
  • Websitehttps://www.ekfdiagnostics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Renalytix PLC2.22m-15.08m24.47m45.00------11.03-0.0601-0.06010.0081-0.01560.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Aptamer Group PLC1.20m-2.42m25.62m31.00--13.69--21.30-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Aoti Inc47.22m1.74m44.01m80.0020.753.3512.680.9320.01990.01990.47440.12341.322.174.65--4.87--6.54--88.13--3.69--2.542.810.5269--32.88--78.55------
Ondine Biomedical Inc1.19m-12.89m46.92m43.00--102.52--39.50-0.0354-0.03540.00320.00090.34470.57718.03---373.83---4,807.85--65.77---1,084.66--0.7948--0.4333--70.32---32.51------
Inspecs Group PLC192.83m-3.31m69.64m1.65k--0.78167.460.3612-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
Creo Medical Group PLC2.20m12.60m72.18m133.005.921.195.1932.810.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
SDI Group PLC69.29m4.59m85.75m504.0019.071.679.461.240.0430.0430.64970.49230.7692--5.78137,484.105.127.085.818.87--63.936.658.601.195.750.33630.000.502721.99-5.848.9911.55--
EKF Diagnostics Holdings PLC50.22m6.12m106.26m297.0018.221.549.672.120.01350.01350.11090.15970.62093.167.34165,745.907.985.798.776.7649.7949.4212.868.623.47--0.0152---4.592.25165.3911.163.02--
Tristel Plc46.46m6.64m200.97m265.0030.376.0721.294.330.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Advanced Medical Solutions Group plc220.30m9.12m477.60m1.50k52.171.8615.712.170.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Data as of Feb 06 2026. Currency figures normalised to EKF Diagnostics Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

68.47%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 20 Oct 2025131.38m30.22%
Gresham House Asset Management Ltd. (Investment Management)as of 24 Mar 202551.14m11.76%
Liontrust Investment Partners LLPas of 18 Sep 202548.57m11.17%
Schroder Investment Management Ltd.as of 16 Jun 202527.25m6.27%
Ruffer LLPas of 24 Mar 202522.78m5.24%
Castlefield Investment Partners LLPas of 31 Jul 20253.72m0.86%
Octopus Investments Ltd.as of 01 Dec 20253.63m0.84%
AXA Investment Managers UK Ltd.as of 01 Dec 20253.37m0.78%
Canaccord Genuity Wealth Ltd.as of 30 Sep 20253.00m0.69%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 20252.81m0.65%
More ▼
Data from 31 Mar 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.